Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03135860 |
Recruitment Status :
Terminated
(This was an exploratory open-label study and has met its initial objectives)
First Posted : May 1, 2017
Last Update Posted : August 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of long term iNO administrationusing the device INOpulse for 4 weeks in relation to Patient Reported Outcome (PRO) and exercise tolerance in subjects with WHO Group 3 PH associated with COPD on LTOT.
Changes from baseline to 4 weeks of pulsed iNO and after 2 weeks of withdrawal from pulsed iNO will be evaluated.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
COPD Pulmonary Hypertension Chronic Obstructive Pulmonary Disease | Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr | Early Phase 1 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | Exploratory Single Arm Study |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Exploratory Study to Assess the Effect of Pulsed Inhaled Nitric Oxide on Functional Respiratory Imaging Parameters in Subjects With WHO Group 3 Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long Term Oxygen Therapy (LTOT). |
Actual Study Start Date : | October 2016 |
Actual Primary Completion Date : | August 21, 2017 |
Actual Study Completion Date : | August 21, 2017 |

Arm | Intervention/treatment |
---|---|
Experimental: Inhaled Nitric Oxide 30mcg/kg/IBW/hr
Inhaled nitric oxide 30 mcg/kg IBW/hr NO will be administered through the InoPulse Device open label for 4 weeks
|
Drug: Inhaled Nitric Oxide 30mcg/kg IBW/hr
Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
Other Name: iNO, NO, |
- change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO after 4 weeks of treatment with iNO as measured by HRCT. [ Time Frame: After 4 weeks of treatment ]The primary endpoint in this exploratory study is the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO after 4 weeks of treatment with iNO as measured by HRCT.
- Blood vessel % and density on lobar level [ Time Frame: after 4 weeks of treatment ]are the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Blood vessel % and density on lobar level
- • Blood vessel % and density on lobal level compared among patients with emphysema, chronic bronchitis or combined emphysema and chronic bronchitis as assessed by HRCT [ Time Frame: after 4 week of treatment ]are the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Blood vessel % and density on lobal level compared among patients with emphysema, chronic bronchitis or combined emphysema and chronic bronchitis as assessed by HRCT
- Total lung volume at TLC [ Time Frame: after 4 week of treatment ]the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Total lung Volume at TLC
- Lobar volumes at TLC [ Time Frame: after 4 weeks of treatment ]the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Lobar volumes at TLC
- Internal airflow distribution based on lobar expansion [ Time Frame: after 4 weeks of treatment ]the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Internal airflow distribution based on lobar expansion
- Airway volume down to generation 8-10 at TLC [ Time Frame: After 4 weeks of treatment ]the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Airway volume down to generation 8-10 at TLC
- Computational Fluid Dynamics (CFD)-based resistance on lobar level [ Time Frame: after 4 weeks of treatment ]change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Computational Fluid Dynamics (CFD)-based resistance on lobar level
- Ventilation/perfusion (V/Q) matching [ Time Frame: after 4 weeks of treatment ]the change in lobar blood volume at total lung capacity with iNO and the change in lobar blood volume with iNO in Ventilation/perfusion (V/Q) matching
- Spirometry [ Time Frame: after 4 weeks of treatment ]the changes from baseline measured by HRCT with pulsed iNO and after dosing with pulsed iNO in Spirometry
- Change from baseline 6MWD; Borg CR10 Dyspnea and Leg Fatigue Score ; PRO [ Time Frame: after 4 weeks of treatment two weeks of withdrawal ]Change in baseline to 4 weeks of pulsed iNO and after 2 weeks of withdrawal from pulsed iNO in:6MWD; Borg CR10 Dyspnea and Leg Fatigue Score ; PRO
- Change from baseline to 4 weeks of treatment and two weeks of withdrawal [ Time Frame: after 4 weeks of treatment two weeks of withdrawal ]• Right Ventricular (RV) and Left Ventricular (LV) size and function, PAP as measured by 2D-echocardiogram with Doppler

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 85 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 1. Male or female patient 2. A confirmed diagnosis of COPD by the Global initiative for chronic Obstructive Lung Disease (GOLD) criteria 3. Pulmonary hypertension will be defined as sPAP ≥ 38 mmHg as determined by echocardiogram (not obtained within ± 7 days of an exacerbation) within the past 12 months.
4. Current or former smokers with at least 10 pack-years of tobacco cigarette smoking before study entry 5. Age ≥ 40 years, ≤ 85 years 6. A post-bronchodilatory FEV1/FVC < 0.7 and a FEV1 < 60% predicted (values obtained within 6 months prior to screening can be used unless obtained within ± 7 days of an exacerbation; otherwise, the test must be performed during screening) 7. Receiving LTOT for ≥ 3 months and ≥ 10 hours per day as determined by history 8. Females of childbearing potential must have a negative pre-scan urine pregnancy test 9. Signed informed consent prior to the initiation of any study mandated procedures or Assessments
Exclusion Criteria:
-
1. Males who have the intention to father a child during the study. 2. A diagnosis of asthma or other non-COPD respiratory disease, in the opinion of the Investigator 3. Lack of patency of nares upon physical examination 4. Experienced during the last month an exacerbation requiring:
- start of or increase in systemic oral corticosteroid therapy and/or
- hospitalization 5. Left ventricular dysfunction as measured by:
- Screening echocardiographic evidence of left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] < 40%), or
- Screening echocardiographic evidence of left ventricular diastolic dysfunction >moderate (i.e., > Grade 3), or
-
Any history of pulmonary capillary wedge pressure (PCWP), left atrial pressure (LAP) or left ventricular end diastolic pressure (LVEDP) > 18 mmHg as measured during cardiac catheterization within the past 6 months unless documented to have resolved by a subsequent cardiac catheterization 6. Renal impairment (i.e., an estimated GFR CKD-EPI < 30 ml/min/1.73 m2) or history of renal failure using the equation:
Men:
crs< 0.9 mg/dL: eGFRCKD-EPI = 141 × (crs /0.9)-0.411 × 0.993Age crs≥ 0.9 mg/dL: eGFRCKD-EPI = 141 × (crs /0.9)-1.209 × 0.993Age
Woman:
crs< 0.7 mg/dL: eGFRCKD-EPI = 144 × (crs /0.7)-0.329 × 0.993Age crs≥ 0.7 mg/dL: eGFRCKD-EPI = 144 × (crs /0.7)-1.209 × 0.993Age where crs= Normal and elevated serum creatinine Subjects with possible compromised kidney function (i.e., Glomerular Filtration Rate estimated using the Modification of Diet in Renal Disease equation [eGFR CKD-EPI] between 30 and 60 ml/min/1.73 m2) may be enrolled provided the Radiology Department and Principal Investigator review the medical records of subjects with an eGFR CKD-EPI between 30 and 60 ml/min/1.73 m2 in order to confirm the contrast agent can be safely administered to these subjects and approval by both the Radiology Department and Principal Investigator must be obtained before enrolling these subjects.
7. Known allergy to contrast media. 8. Clinically significant valvular heart disease that may contribute to PH, including mild or greater aortic valvular disease (aortic stenosis or regurgitation) and/or moderate or greater mitral valve disease (mitral stenosis or regurgitation), or status post mitral valve replacement 9. Use within 30 days of screening or current use of approved PH medications such as sildenafil or bosentan (use of Cialis® or Viagra® for erectile dysfunction is permitted) 10. Use of investigational drugs or devices within 30 days prior to enrollment into the study 11. Any underlying medical or psychiatric condition that, in the opinion of the Investigator, makes the subject an unsuitable candidate for the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03135860
Belgium | |
Antwerp University Hospital | |
Edegem, Belgium, 2650 |
Study Director: | Ed Parsley, DO | Bellerophon Therapeutics |
Responsible Party: | Bellerophon |
ClinicalTrials.gov Identifier: | NCT03135860 |
Other Study ID Numbers: |
PULSE-COPD-007 |
First Posted: | May 1, 2017 Key Record Dates |
Last Update Posted: | August 10, 2022 |
Last Verified: | September 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Product Manufactured in and Exported from the U.S.: | Yes |
Inhaled Nitric Oxide COPD Chronic Obstructive Pulmonary Disease Idopathic Pulmonary Fibrosis Long Term Oxygen Therapy (LTOT) |
Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive Hypertension, Pulmonary Hypertension Vascular Diseases Cardiovascular Diseases Respiratory Tract Diseases Nitric Oxide Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents |
Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Free Radical Scavengers Antioxidants Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Endothelium-Dependent Relaxing Factors Vasodilator Agents Gasotransmitters Protective Agents |